UC
Expiry date: 2022-07-31
PRODUCT DESCRIPTION
Ulcerative Colitis is one of the most common Inflammatory bowel diseases, characterized by inflamed and ulcerating GIT mucosa, effecting the surface as well as the deeper smooth muscle layers and nerve cells. The exact cause is unknown, however the inflammatory drive appears to be linked to the enteric neuroimmune-endocrine system and neuropeptide dysregulation. There is also appears to be a genetic link of immune dysregulation in response to abnormal microbiota.
Indications:
- Ulcerative Colitis
- Bechet’s disease
- Chron’s disease
- Colitis
- IBD
RECOMMENDED USAGEPanaxe
Take one to two capsules daily, up to four maximum for short periods of time.
COMPOSITION
| Serving Size: 1 Capsule | Amount Per Serving |
| Extract dry conc. (6:1) equiv. | |
| Coptis japonica - root | 1.14 g |
| Equiv. Berberine | 100 mg |
| Extract dry conc. (5:1) equiv. to: | |
| Glycyrrhiza glabra - root | 350 mg |
| Equiv. Glycyrrhizinic acid | 35 mg |
| Glycyrrhiza uralensis - root / rhizome | 125 mg |
| Panax ginseng - root and rhizome | 300 mg |
| Pinellia ternata - root and rhizome | 400 mg |
| Scutellaria baicalensis - root | 250 mg |
| Zizyphus sativa - fruit | 125 mg |
OTHER INGREDIENTS
Vegetable cellulose (hypromellose), vegetable stearic acid, microcrystalline cellulose and vegetable magnesium stearate.
DOES NOT CONTAIN
NoneKeep lid tightly closed and store in a cool dry place.
PRODUCT FORM
Capsule
WARNINGS/CONTRAINDICATIONS
- Contraindicated Pregnancy and breast-feeding
- Caution: Anticoagulant therapy such as Warfarin or high dose Curcumin HT, CoQ10, Tanshionone.
- May inhibit CYP3A4 and CYP2B6.
- Avoid potassium depleting diuretics.
- Berberine can effect normal GIT flora, may require supplementation with pro-biotics if used for longer than 2 months.
- Effect on other immune suppressants - unknown.
- Avoid long term use in Colon cancer.